文献速递心力衰竭与心肌病

射血分数保留心衰中中心性肥胖近乎普遍存在:PARAGON-HF试验

Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial.
PubMed 文献 · Eur Heart J · 2025-01-01

PARAGON-HF试验随机纳入4796例射血分数≥45%的心衰患者,比较沙库巴曲缬沙坦与缬沙坦。WHtR较BMI更线性关联心衰结局,且未观察到BMI的肥胖-生存悖论。

要点

  • WHtR较BMI更稳健地关联心衰住院风险,且未出现肥胖-生存悖论。

核心结论

  • 在PARAGON-HF中,与BMI不同,几乎所有HFpEF患者存在中心性肥胖(以WHtR评估),且不良心衰事件风险与WHtR关联更稳健。
  • 这些数据挑战当前依赖BMI作为肥胖指标的做法,并提示中心性肥胖是HFpEF的普遍特征,而非仅限肥胖相关HFpEF亚组。

研究设计与样本

  • PARAGON-HF试验随机纳入4796例心衰且射血分数≥45%的患者,分配至缬沙坦或沙库巴曲缬沙坦。
  • 本分析刻画BMI与WHtR和临床特征、结局及脑啡肽酶抑制反应之间的关联。

主要发现

  • 较高BMI和WHtR均与总心衰住院风险较高相关;与BMI相比,WHtR与心衰结局呈线性关联,并识别出更高比例风险特别升高(即30%或以上)的患者。
  • 未校正分析中BMI显现肥胖-生存悖论(即肥胖程度较高者结局改善),但WHtR未观察到该现象。
  • 脑啡肽酶抑制在较高BMI和WHtR患者中对心衰结局似有更大效应,但与肥胖指标交互分析未显示跨肥胖值范围的显著异质性。

临床怎么用

  • WHtR较BMI更线性关联心衰住院风险,可用于识别风险特别升高(30%或以上)的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: An expansion of fat mass is an integral feature of patients with heart failure and preserved ejection fraction (HFpEF). While body mass index (BMI) is the most common anthropometric measure, a measure of central adiposity-the waist-to-height ratio (WHtR)-focuses on body fat content and distribution; is not distorted by bone or muscle mass, sex, or ethnicity; and may be particularly relevant in HFpEF. METHODS: The PARAGON-HF trial randomized 4796 patients with heart failure (HF) and ejection fraction ≥45% to valsartan or sacubitril/valsartan. The current work characterizes the association of BMI and WHtR with clinical features, outcomes, and the response to neprilysin inhibition. RESULTS: About half (49%) of the participants were considered obese by BMI (≥30 kg/m2), but nearly every patient (96%) had central adiposity (WHtR ≥.5). Among patients who were not obese (BMI <30 kg/m2), 860 (37%) had marked central adiposity (WHtR ≥.6). Higher BMI and WHtR were both associated with higher risk of total HF hospitalizations, but as compared with BMI, WHtR was linearly associated with HF outcomes and identified a higher proportion of patients who had a particularly elevated risk (i.e. 30% or greater). An obesity-survival paradox (i.e. improved outcomes in those with greater adiposity) was apparent with BMI in unadjusted analyses, but it was not observed with WHtR. Although neprilysin inhibition appeared to have greater effects on HF outcomes in patients with higher BMI and WHtR, analyses of interaction with obesity metrics did not show significant heterogeneity across the range of values for adiposity. CONCLUSIONS: In PARAGON-HF, in contrast with BMI, nearly every patient with HFpEF had central adiposity (as assessed by WHtR), and the risks of adverse HF events were more robustly related to WHtR. These data challenge the current reliance on BMI as an appropriate metric of adiposity, and they suggest that-rather than obesity-related HFpEF being regarded as a select HFpEF subgroup-central adiposity is a ubiquitous feature of HFpEF. CLINICAL TRIAL REGISTRATION: https://www.clinicaltrials.gov. Unique identifier: NCT01920711.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Peikert, Vaduganathan, Claggett, et al. Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial. Eur Heart J. 2025. PMID: 39873282. doi:10.1093/eurheartj/ehaf057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。